证券代码：600789 证券简称：鲁抗医药 公告编号：2025—029 山东鲁抗医药股份有限公司 关于向特定对象发行股票申请文件的审核问询函 回复及募集说明书等申请文件更新的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东鲁抗医药股份有限公司（以下简称"公司"）于近期收到上海证券交易 所（以下简称"上交所"）出具的《关于山东鲁抗医药股份有限公司向特定对象 发行股票申请文件的审核问询函》（上证上审（再融资）〔2025〕137 号，以下 简称《问询函》），上交所审核机构对公司向特定对象发行股票申请文件进行了 审核，并形成了问询问题。 公司收到《问询函》后，会同相关中介机构就《问询函》所列问题进行了认 真研究和逐项落实，根据相关要求对《问询函》有关问题进行了说明和论证，同 时对募集说明书等申请文件的部分内容进行了相应补充和修订，具体内容详见公 司同日在上海证券交易所网站（www.sse.com.cn）披露的《关于山东鲁抗医药股 份有限公司向特定对象发行股票申请文件的审核问询函的回复》等文件。 公司本次向特定对象发行股 ...

键凯科技688356 时间: 2025年6月17日星期二 53.80分综合得分 较强 趋势方向 主力成本分析 69.91 元 当日主力成本 60日主力成本 周期内涨跌停 过去一年内该股 73.16 元 5日主力成本 71.53 元 20日主力成本 63.39 元 涨停 0次 次 北向资金数据 持股量23.18万股 占流通比0.38% 昨日净买入-2.55万股 昨日增仓比-0.042% 5日增仓比-0.083% 20日增仓比0.071% 跌停 0 技术面分析 76.95 短期压力位 72.58 短期支撑位 中期支撑位 股价跌破短期支撑位，短线观望为宜； 目前中期趋势不慎明朗，静待主力资金选择方向 K线形态 行情将见顶回落 79.15 中期压力位 61.45 ★大阴烛★ 后市向淡,发生逆转 ★三只乌鸦★ 可能见顶回落 ★双飞乌鸦★ 化学制药 -1.43%、医疗器械概念 0.09%、创新药 -1.96%等 （以上内容为自选股写手差分机完成，仅作为用户看盘参考，不能作为操作依据。） 风险提示：以上内容仅作为作者或者嘉宾的观点，不代表和讯的任何立场，不构成与和讯相关的任何投 资建议。在作出任何投资决定前，投资者应根据自 ...

Financial Sector - Agricultural Bank of China has a market value of 1,970.40 billion with a trading volume of 0.869 billion, closing at 5.63, unchanged [2] - Bank of China has a market value of 1,577.92 billion with a trading volume of 0.922 billion, closing at 5.36, down by 0.02 (-0.37%) [2] - China Construction Bank has a market value of 2,548.30 billion with a trading volume of 0.931 billion, closing at 7.15, up by 0.01 (+0.14%) [2] - Ping An Bank has a market value of 228.21 billion with a trading volume of 0.704 billion, closing at 11.76, down by 0.03 (-0.25%) [2] Insurance Sector - China Pacific Insurance has a market value of 379.00 billion with a trading volume of 0.498 billion, closing at 8.57, down by 0.40 (-1.10%) [3] - China Life Insurance has a market value of 986.45 billion with a trading volume of 0.474 billion, closing at 54.17, down by 0.14 (-1.61%) [3] Alcohol Industry - Kweichow Moutai has a market value of 1,779.91 billion with a trading volume of 2.309 billion, closing at 174.22, up by 2.00 (+1.16%) [3] - Wuliangye Yibin has a market value of 457.02 billion with a trading volume of 1.048 billion, closing at 1416.90, down by 5.39 (-0.38%) [3] Semiconductor Sector - Northern Huachuang has a market value of 222.64 billion with a trading volume of 2.390 billion, closing at 135.55, down by 2.80 (-2.02%) [3] - Cambrian has a market value of 240.46 billion with a trading volume of 1.292 billion, closing at 416.79, up by 4.40 (+1.07%) [3] Automotive Sector - BYD has a market value of 1,888.46 billion with a trading volume of 1.575 billion, closing at 5.75, down by 0.74 (-0.21%) [3] - Great Wall Motors has a market value of 183.33 billion with a trading volume of 0.183 billion, closing at 343.69, unchanged [3] Energy Sector - Sinopec has a market value of 252.79 billion with a trading volume of 0.817 billion, closing at 5.98, up by 0.07 (+1.18%) [3] - China National Offshore Oil Corporation has a market value of 725.05 billion with a trading volume of 0.866 billion, closing at 16.32, up by 0.07 (+0.78%) [3] Coal Industry - Shaanxi Coal and Chemical Industry has a market value of 193.99 billion with a trading volume of 1.408 billion, closing at 247.40, up by 0.07 (+0.18%) [3] - China Shenhua Energy has a market value of 777.06 billion with a trading volume of 0.450 billion, closing at 39.11, up by 0.23 (+1.16%) [3] Other Sectors - Longyuan Power has a market value of 744.32 billion with a trading volume of 1.402 billion, closing at 9.43, down by 0.04 (-0.13%) [4] - CITIC Securities has a market value of 393.93 billion with a trading volume of 0.777 billion, closing at 18.58, down by 0.10 (-0.37%) [4] - Mindray Medical has a market value of 169.70 billion with a trading volume of 0.566 billion, closing at 232.70, up by 0.18 (+0.36%) [4]

Core Viewpoint - The article highlights the increasing regulatory scrutiny in the capital market, emphasizing a "zero tolerance" approach towards financial fraud, information disclosure violations, and fund misappropriation by listed companies. Group 1: ST Longyu - ST Longyu has been placed under investigation by the China Securities Regulatory Commission (CSRC) for suspected information disclosure violations, with a total of 8.7 billion yuan in fund misappropriation involved [1][2] - The company’s controlling shareholder and related parties have non-operational fund misappropriation totaling 9.18 billion yuan, of which 8.68 billion yuan remains unpaid [2] - The audit report for ST Longyu's 2023 annual report was issued with a "disclaimer of opinion," leading to increased delisting risks for the company [2] Group 2: ST Huamei - ST Huamei has been formally investigated by the CSRC for suspected information disclosure violations, with a self-reported non-operational fund misappropriation of 14.35 billion yuan [3][4] - The company reported significant fund flows lacking real commercial substance, with total outflows of 81.39 billion yuan and inflows of 68.52 billion yuan [3] - The ongoing investigation will impact the company's compliance risks and market reputation [3] Group 3: Guangji Pharmaceutical - Guangji Pharmaceutical has received a notice from the CSRC regarding an investigation for suspected information disclosure violations, following a previous warning from the Hubei Securities Regulatory Bureau [4][5] - The company acknowledged accounting errors in its financial reports, leading to adjustments in previously reported revenue and costs [4] - The CSRC's investigation marks an escalation in regulatory scrutiny regarding the company's compliance with information disclosure requirements [5] Group 4: Xiangyuan Cultural Tourism - Xiangyuan Cultural Tourism and its actual controller have been placed under investigation by the CSRC for suspected information disclosure violations [5] - The specific details of the violations have not yet been disclosed, but the investigation will assess the company's compliance with securities laws [5] - The outcome of the investigation is expected to be a focal point for market participants [5]

雅本化学股份有限公司总经理工作细则 雅本化学股份有限公司 总经理工作细则 第一章 总则 第一条 为提高公司管理效率和科学管理水平，根据《中华人民共和国公司法》 等有关法律、法规、规范性文件以及《雅本化学股份有限公司章程》（以下称"《公 司章程》"）的规定，制定本细则。 第二条 本细则对公司经营管理层及相关人员（包括总经理、副总经理和财务 负责人）的职责权限、主要管理职能及工作内容进行明确规定。 第三条 公司经营管理层履行职权除应遵守本细则的规定外，还应符合相关法 律、法规、规范性文件和《公司章程》的规定。 第二章 总经理的任免资格和任免程序 第四条 公司经营管理层设总经理一名，副总经理若干名，财务负责人一名。 总经理及其他高级管理人员每届任期三年，连聘可以连任。 第五条 公司经营管理层的人员变动应经董事会审议批准。总经理、副总经理、 财务负责人必须专职，不得在控股股东、实际控制人及其控制的其他企业中担任除 董事、监事以外的其他职务，不得在控股股东、实际控制人及其控制的其他企业领 薪。 第六条 总经理任职应该具备下列条件： （一）具有丰富的经济、管理知识及企业经营、管理实际经验；熟悉国家有关 法律、法规及政策； ...

Core Points - The internal control system of Yabont Chemical Co., Ltd. aims to strengthen risk management, improve operational efficiency, enhance information reliability, and ensure legal compliance to achieve strategic goals [2][3][4] Group 1: Objectives and Framework - The internal control objectives include risk control, operational efficiency improvement, information reliability enhancement, and legal compliance [2][3] - The internal control framework encompasses environmental control, business control, accounting system control, electronic information system control, information transmission control, and internal audit control [4][5] Group 2: Basic Elements of Internal Control - The basic elements of the internal control system include internal environment, goal setting, factor identification, risk assessment, risk response, control activities, information communication, and supervision [3][4][5] Group 3: Control Activities in Business Cycles - The internal control system covers various business cycles, including sales and collection, procurement and payment, production, fixed assets, monetary funds, related party transactions, financing, investment, research and development, and human resource management [5][6][7] Group 4: Management of Subsidiaries and Related Transactions - The company establishes control policies for managing subsidiaries, ensuring they develop their internal control systems and report significant matters to the parent company [8][9] - Related transactions must adhere to principles of honesty, equality, and fairness, with clear approval processes and disclosure requirements [10][11][12] Group 5: External Guarantees and Fundraising - The internal control for external guarantees emphasizes legality, prudence, mutual benefit, and safety, with strict risk control measures [12][13] - The company must establish a management method for fundraising, ensuring funds are used according to specified purposes and tracked for compliance [14][15] Group 6: Major Investments and Information Control - Major investments require thorough feasibility studies and risk assessments, with ongoing monitoring of project execution and financial performance [16][17] - An information disclosure management system is established to ensure timely and accurate reporting of significant information, with confidentiality measures in place [18][19] Group 7: Internal Audit and Evaluation - An internal audit department is set up to oversee business activities, risk management, and internal controls, reporting directly to the board [20][21] - The company conducts regular evaluations of its internal control effectiveness, addressing any identified deficiencies promptly [22][23]

雅本化学股份有限公司内幕信息知情人登记管理制度 雅本化学股份有限公司 内幕信息知情人登记管理制度 第一章 总则 第一条 为加强雅本化学股份有限公司（以下简称"公司"）内幕信息管理，做好内 幕信息保密工作，维护信息披露的公平原则，保护广大投资者的合法权益，根据《中 华人民共和国公司法》《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司监管指引第 5 号——上市公司内幕信息知情人登记管理制度》《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》等有关法律法规以及《雅本化学股份有限公司章程》（以下 简称"《公司章程》"）、《信息披露管理制度》等规定，结合公司实际情况，制定 本制度。 第二条 董事会应当按照相关规则要求及时登记和报送内幕信息知情人档案，并保 证内幕信息知情人档案真实、准确和完整，董事长为主要责任人。公司董事会秘书负 责办理公司内幕信息知情人的登记入档事宜和报送事宜。董事长与董事会秘书应当对内 幕信息知情人档案的真实、准确和完整签署书面确认意见。董事会办公室具体负责公 司内幕信息的日常管理工作。 第三条 公司董事、高级管理人员及 ...

Financial Sector - The banking sector continued its upward trend in the afternoon session, contributing positively to the FTSE China A50 Index [1] - China Life Insurance, China Pacific Insurance, and China Ping An reported market capitalizations of 385.19 billion, 351.05 billion, and 989.18 billion respectively, with trading volumes of 1.155 billion, 2.698 billion, and 1.079 billion [4] Alcohol Industry - Kweichow Moutai, Shanxi Fenjiu, and Wuliangye had market capitalizations of 1,786.68 billion, 210.10 billion, and 459.08 billion respectively, with trading volumes of 3.192 billion, 6.060 billion, and 1.760 billion [4] - Kweichow Moutai's stock price decreased by 4.66 (-0.33%), while Wuliangye increased by 1.12 (+0.65%) [4] Semiconductor Industry - Northern Huachuang, Haiguang Information, and Cambricon Technologies had market capitalizations of 220.29 billion, 249.45 billion, and 321.57 billion respectively, with trading volumes of 1.075 billion, 2.756 billion, and 2.048 billion [4] - Northern Huachuang's stock price fell by 7.35 (-1.22%) [4] Automotive Industry - BYD, Great Wall Motors, and Shanghai-Kunming High-Speed Railway had market capitalizations of 1,892.53 billion, 183.68 billion, and 281.32 billion respectively, with trading volumes of 3.509 billion, 0.627 billion, and 0.348 billion [4] - BYD's stock price decreased by 1.57 (-0.45%) [4] Energy Sector - COSCO Shipping Holdings, Sinopec, and China National Petroleum Corporation had market capitalizations of 716.56 billion, 1,650.85 billion, and 249.69 billion respectively, with trading volumes of 1.159 billion, 1.722 billion, and 1.019 billion [4] - Sinopec's stock price increased by 0.03 (+0.33%) [4] Coal Industry - Shaanxi Coal and Chemical Industry, China Shenhua Energy, and CATL had market capitalizations of 191.77 billion, 1,124.60 billion, and 775.67 billion respectively, with trading volumes of 3.014 billion, 0.922 billion, and 0.608 billion [4] - Shaanxi Coal's stock price decreased by 0.22 (-0.56%) [4] Food and Beverage Sector - China National Nuclear Power, Dongfang Fortune, and Haitian Flavoring had market capitalizations of 745.30 billion, 193.55 billion, and 343.42 billion respectively, with trading volumes of 1.574 billion, 0.521 billion, and 5.827 billion [5] - China National Nuclear Power's stock price decreased by 0.16 (-0.52%) [5] Consumer Electronics - Heng Rui Medicine, Industrial Fulian, and Luxshare Precision had market capitalizations of 355.01 billion, 421.40 billion, and 231.31 billion respectively, with trading volumes of 2.645 billion, 3.052 billion, and 2.100 billion [5] - Heng Rui's stock price increased by 0.32 (+1.53%) [5] Logistics Industry - Mindray Medical, SF Holding, and Wanhua Chemical had market capitalizations of 169.95 billion, 248.64 billion, and 286.88 billion respectively, with trading volumes of 1.343 billion, 0.896 billion, and 1.030 billion [5] - Mindray's stock price increased by 0.81 (+1.65%) [5] Telecommunications - Zijin Mining, China State Construction, and China Unicom had market capitalizations of 500.19 billion, 236.77 billion, and 164.76 billion respectively, with trading volumes of 2.515 billion, 0.784 billion, and 0.731 billion [5] - Zijin Mining's stock price decreased by 0.33 (-1.72%) [5]

Core Insights - Hanyu Pharmaceutical (300199) has recently conducted investor research, discussing the progress of the HY3003 new drug project, its layout in the innovative drug field, and overseas market expansion [1][2] Group 1: HY3003 New Drug Project - The HY3003 project has completed preclinical candidate compound screening and raw material process development, officially entering the raw material pilot scale-up phase, which validates the producibility of the molecular structure for subsequent IND application and clinical transformation [1] - HY3003 is a GLP-1R/GIPR/GCGR receptor agonist developed using AI peptide chip technology, aimed at weight loss indications [1] - The project employs a multi-formulation parallel development strategy, including weekly, ultra-long-acting monthly, and oral formulations, with the ultra-long-acting formulation designed to reduce dosing frequency and improve medication adherence [1] Group 2: siRNA and Other Drug Developments - The company is also developing siRNA drugs such as Inclisiran and Zilebesiran for treating high cholesterol and hypertension, as well as Pegcetacoplan for treating geographic atrophy [1] Group 3: Overseas Market Expansion - Currently, the company's raw materials are sold to over 20 countries and regions, with formulations licensed in over 90 countries and regions [2] - The company has signed cooperation agreements for the semaglutide injection (weekly formulation) and oral tablets in markets including China, Brazil, Egypt, Mexico, Eurasian Union, GCC member countries, and North Africa [2] - The company has completed the enrollment of all participants in the Phase III clinical trial for semaglutide injection as of January this year, with plans to submit for approval in China by 2026, followed by the US and other global markets [2] Group 4: Future Pipeline - Hanyu Pharmaceutical has a rich pipeline of peptide and small nucleic acid formulations, planning to launch no less than 20 formulations over the next 10 years, including innovative drugs, micro-innovative drugs, and ANDA [2]

（原标题：和讯投顾都业华：关注近期异动板块，可尝试用多头思路寻找机会） 6月16日，和讯投顾都业华对几个影响力较大且备受关注的板块进行了分析。 上周五分析时，虽当时阴线未现，但指出该板块前高位置有放量阳线，套人情况明显，突破前高难度较 大。当时还提到，板块虽有两波上涨引起关注，但过前高后仅是对称震荡，做不出三板。若往上突破， 前高位置难过；若过不去，很可能回下沿。星期五的走势正是如此。从经验看，当前位置是重要支撑， 但支撑未到，小级别上未止跌。对于持有证券股的投资者，建议定止损，这是做风控的重要方案，多数 交易大师也采用止损方式。对于想买证券的投资者，需等其止跌，同时要考虑止跌位置和性价比。证券 板块目前并非特别强，不在舞台中央，但对市场影响大、有人气。 与数字货币对比，目前看走势未结束。从15分钟图看，若组成对称震荡，可看作机会，但也有另一种难 认的震荡走势。与数字货币相比，可控核聚变更强，因为数字货币前高没过，上周五已出现较大阴线。 此前分析A50时，在未看到中东军事冲突新闻的情况下，提到军工板块前期上过热点，顶着压力震荡， 可定位为强势震荡。现在军工板块阳线起来且放量，但从板块角度讲，尚未突破。后续走势 ...